1st Quarter - Report

BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC for BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC

Period 1st Quarter 2018 Filed Apr 20, 2018 Signed by Edward Buckley

Official filing
Firm
BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
Client
BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
Income
—
Expenses
$100,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Alcohol and Drug Abuse ALC

HR 5202 - Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018 , S. 916 - Protecting Patient Access to Emergency Medications Act of 2017: To amend the Controlled Substances Act to provide for the delivery of a controlled substance by a pharmacy to an administering practitioner.

LobbyistCovered position, as disclosed
EDWARD BUCKLEY —

Contacted: HOUSE OF REPRESENTATIVES; Substance Abuse & Mental Health Services Administration (SAMHSA); Office of Natl Drug Control Policy (NDCP); SENATE; Health & Human Services, Dept of (HHS)

Bills named: S. 916 (115th), H.R. 5202 (115th)

Health Issues HCR

HR 5202 - Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018 , S. 916 - Protecting Patient Access to Emergency Medications Act of 2017: To amend the Controlled Substances Act to provide for the delivery of a controlled substance by a pharmacy to an administering practitioner.

LobbyistCovered position, as disclosed
EDWARD BUCKLEY —

Contacted: Substance Abuse & Mental Health Services Administration (SAMHSA); Office of Natl Drug Control Policy (NDCP); Health & Human Services, Dept of (HHS); SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 916 (115th), H.R. 5202 (115th)

Medicare/Medicaid MMM

HR 5202 - Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018 , S. 916 - Protecting Patient Access to Emergency Medications Act of 2017: To amend the Controlled Substances Act to provide for the delivery of a controlled substance by a pharmacy to an administering practitioner.

LobbyistCovered position, as disclosed
EDWARD BUCKLEY —

Contacted: Health & Human Services, Dept of (HHS); Substance Abuse & Mental Health Services Administration (SAMHSA); Office of Natl Drug Control Policy (NDCP); HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 5202 (115th), S. 916 (115th)

Pharmacy PHA

HR 5202 - Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018 , S. 916 - Protecting Patient Access to Emergency Medications Act of 2017: To amend the Controlled Substances Act to provide for the delivery of a controlled substance by a pharmacy to an administering practitioner.

LobbyistCovered position, as disclosed
EDWARD BUCKLEY —

Contacted: Substance Abuse & Mental Health Services Administration (SAMHSA); SENATE; HOUSE OF REPRESENTATIVES; Office of Natl Drug Control Policy (NDCP); Health & Human Services, Dept of (HHS)

Bills named: H.R. 5202 (115th), S. 916 (115th)

Insurance INS

HR 5202 - Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018 , S. 916 - Protecting Patient Access to Emergency Medications Act of 2017: To amend the Controlled Substances Act to provide for the delivery of a controlled substance by a pharmacy to an administering practitioner.

LobbyistCovered position, as disclosed
EDWARD BUCKLEY —

Contacted: SENATE; Office of Natl Drug Control Policy (NDCP); Health & Human Services, Dept of (HHS); Substance Abuse & Mental Health Services Administration (SAMHSA); HOUSE OF REPRESENTATIVES

Bills named: H.R. 5202 (115th), S. 916 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.